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Abstract: A great variety of computational approaches support drug design processes, helping
in selection of new potentially active compounds, and optimization of their physicochemical and
ADMET properties. Machine learning is a group of methods that are able to evaluate in relatively
short time enormous amounts of data. However, the quality of machine-learning-based prediction
depends on the data supplied for model training. In this study, we used deep neural networks for
the task of compound activity prediction and developed dropout-based approaches for estimating
prediction uncertainty. Several types of analyses were performed: the relationships between the
prediction error, similarity to the training set, prediction uncertainty, number and standard deviation
of activity values were examined. It was tested whether incorporation of information about prediction
uncertainty influences compounds ranking based on predicted activity and prediction uncertainty
was used to search for the potential errors in the ChEMBL database. The obtained outcome indicates
that incorporation of information about uncertainty of compound activity prediction can be of great
help during virtual screening experiments.
Keywords: machine learning; prediction uncertainty; deep learning; ligands; ChEMBL database
1. Introduction
Computational methods have now become indispensable part of drug design process, supporting
its every stage, from proposing new drug candidates, via optimization of their activity, to tuning their
physicochemical and pharmacokinetic properties and minimizing adverse effects (computer-aided
drug design, CADD) [1–8]. Great desire for new medications for various diseases is an impulse
for conduction of experiments in the field, which causes the exponential growth of the amount of
pharmaceutical-related data that can then be used for modeling of compounds bioactivity and properties.
There is a number of databases storing information about various aspects of biologically active
compounds—from data on compounds activity towards particular target, such as the ChEMBL
database [9] or PDSP [10], through the information on 3-dimensional structure of proteins (PDB) [11],
data on existing drugs (DrugBank) [12] or compounds toxicity (TOXNET) [13]. The information stored
in such databases can be very useful during the design of new compounds with desired biological
activity; however, the great amount of information stored there makes it impossible to be carried
out by simple statistical tools. Therefore, more sophisticated tools need to be use in order to derive
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relationships that can facilitate the process of finding new drug candidates. This is the reason why
machine learning (ML) methods have recently gained such great popularity in the field of drug design.
They are used both to select potential drug candidates from large compounds databases, but also to
generate the structures of new chemical compounds de novo—or to optimize their physicochemical
and pharmacokinetic properties [14–27].
Despite a wide range of possibilities offered by ML methods, there are also problems which leads
to inaccurate predictions of compounds activity or other evaluated properties. First of all, in order to
apply ML methods for dealing with cheminformatic problems, the structures of chemical compounds
need to be properly represented. One of the most popular approaches to this task is fingerprinting that
is translating a compound into the form of a bit string coding information about its structure [28–32].
There are two main types of this way of compound transformation: hashed fingerprints and key-based
fingerprints and each type of compounds translation is connected with losing some pieces of information
about compound structure. For example, in the key-based fingerprints, subsequent positions provide
information about the presence or absence of particular chemical moieties in the molecule; however,
after representing compound in such a form, information about the connections between these moieties
is lost.
Another problem with application of ML methods in the process of selecting new drug candidates
is related to the fact that the already known ligands of a given receptor usually cover relatively narrow
chemical space [33]. It then causes, that if they are used for training a ML model, we obtain correct
predictions on the activity of compounds that are structurally close to the previously examined ones,
but there are difficulties in evaluation of structurally novel compounds. Generalization issues are
difficult to be solved and various approaches have already been tested to improve the prediction
accuracy on the molecules with dissimilar structures to known ligands [34,35].
Each computational model, before application in CADD tasks, needs to be evaluated in terms of
its prediction accuracy. Such retrospective studies are also challenging, as the proper testing approach
needs to be selected. It was already reported in several studies, that cross-validation (CV) with random
splitting leads to overoptimistic results as we rather obtain information on a model that works via
memorizing the training set than generalizing it on new data. However, other splitting approaches
(such as cluster-based or scaffold-based splitting) are also not perfect; they also do not fully solve
the problem of providing information about the ability of a model to evaluate structurally novel
compounds [33,34].
Another problem related to application of computational tools in CADD is the fact that most of
them (not only ML-based, but also pharmacophore modeling or homology modeling when model
evaluation is considered) need first to be trained, which is usually performed on experimental data
stored in various databases. However, as it was already indicated and what is also a subject of this
study, experimental data are not always reproducible and the provided compound activity values are
not always reliable [36].
There are different types of uncertainty that can be considered. Two most important categories of
this problem are epistemic and aleatoric uncertainty. The latter type of uncertainty is sometimes called
also a systematic uncertainty and its source is lack of knowledge of various types. It can be related to
misunderstanding of the analyzed process or missing data of a particular type. Epistemic uncertainty
influences evaluations of events of ‘accident’ types, such as probability of failure of particular machine
and evaluation of probability of human error (when the analyst does not possess enough data to make
proper decision). On the other hand, aleatoric uncertainty is also known as statistical uncertainty and
is related to randomness occurring during experiment (causing differences in the obtained outcome
when experiment is run several times with the same settings) [37].
Out of a wide range of ML models applied in CADD, great popularity is now gained by deep
learning (DL) approaches. DL methods are known for their ability to model complicated dependencies
in data, much more efficiently than their shallow counterparts. In CADD, they are both used for
evaluation of compounds activity and other properties (physicochemical, ADMET), as well as for the
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generation of molecules with properties falling in specific range of values (e.g., with defined solubility,
stability, etc.) [38–45].
There are different approaches to estimate prediction uncertainty. At first, we would like to
remark on the use of the soft-max probabilities in uncertainty estimation. It should be pointed out that
measures calculated solely on the output of soft-max probability distribution are not actually modeling
uncertainty. As shown by Gal et al. [46], the model can be certain (meaning high probability of class
assignment) for a data point that was never seen by the model during training. Given a perfect classifier,
for a sample out of the training distribution, but with some features resembling an specific subgroup
of the training set (e.g., active compounds), we would like to predict the ligand active; however, with
a measurable margin of uncertainty (as the model has not observed such an exact sample before).
The certainty of such activity prediction is the expected outcome in the soft-max distribution, as it does
not provide any additional information about its decision.
In this study, we used a method for uncertainty estimation proposed by Gal et al.—dropout-based
uncertainty. It uses an indeterministic model both during training and evaluation. The stochasticity
is expressed by the dropout mechanic [47], which was originally developed to combat overfitting of
neural networks. In the original formulation, some of the network weights (i.e., neurons) are dropped
out, zeroing their weighs, which in turn means that they do not contribute to the prediction. The set of
neurons that are dropped out is different in each iteration (for each data batch, different neurons are
dropped). In the typical dropout setting, none of the weights are dropped during evaluation, as we
typically want the prediction to be deterministic.
Nevertheless, for the dropout-based uncertainty, the dropout onduring inference is kept. Moreover,
each testing sample is passed through the network multiple times, each with different dropout mask
(i.e., different set of neurons dropped) and prediction statistics are calculated based on those outputs.
Measuring the variance of each run for a given data point yields the model uncertainty.
We would like also to mention two other approaches for estimating model uncertainty. Bayesian
neural networks are a popular framework for models with built-in uncertainty weights, with
Probabilistic Backpropagation [48] as an example have already been used to estimate model uncertainty.
Other approach, related to Bayesian models belongs to the group of Variational Inference methods,
which provide an approximation to Bayesian inference over network’s weights [49]. The drawback of
those methods is computational complexity, whereas the approach used in the study requires only few
additional forwards passes through the model.
In the study, several types of experiments have been performed:
• the relationships between the prediction error, similarity to the training set and prediction
uncertainty for the data from the test set were examined, together with analysis of correlation
between uncertainty and the number of activity values provided—and also between uncertainty
and standard deviation of activity values
• we tested whether incorporation of information about prediction uncertainty improves the
compounds ranking on the basis of predicted activity
• uncertainty of predictions was used to search for the potential errors in the ChEMBL database.
The study was carried out for two sets of targets: 10 targets from previous benchmark
experiments [35] and additional 15 targets from various G protein coupled receptors (GPCRs) families.
The predictions (numerical regression of bioactivity of ligands) were carried out in two settings:
random CV and balanced agglomerative clustering (BAC) for two compounds representations.
2. Results and Discussion
2.1. General Observations
Tables 1 and 2 gather values of mean squared error (MSE) for CV and BAC splitting, together
with the estimation of uncertainty.
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Table 1. Regression results obtained for random CV.
Target Morgan MACCSFP
MSE Dropout MSE Uncertainty MSE Dropout MSE Uncertainty
5-HT1A 0.416 ± 0.02 0.406 ± 0.02 0.318 ± 0.01 0.568 ± 0.04 0.552 ± 0.04 0.580 ± 0.00
ACM1 0.665 ± 0.18 0.660 ± 0.17 0.352 ± 0.01 0.781 ± 0.16 0.763 ± 0.15 0.567 ± 0.01
D2 0.352 ± 0.03 0.344 ± 0.03 0.298 ± 0.01 0.436 ± 0.00 0.420 ± 0.00 0.510 ± 0.00
5-HT2A 0.467 ± 0.03 0.459 ± 0.03 0.319 ± 0.01 0.559 ± 0.06 0.551 ± 0.05 0.523 ± 0.01
5-HT2C 0.494 ± 0.02 0.488 ± 0.02 0.304 ± 0.01 0.532 ± 0.03 0.518 ± 0.02 0.535 ± 0.04
A1 0.429 ± 0.03 0.421 ± 0.03 0.308 ± 0.00 0.479 ± 0.02 0.474 ± 0.02 0.547 ± 0.03
A2A 0.412 ± 0.03 0.406 ± 0.03 0.326 ± 0.01 0.528 ± 0.03 0.515 ± 0.02 0.561 ± 0.02
H3 0.407 ± 0.04 0.399 ± 0.04 0.300 ± 0.01 0.504 ± 0.02 0.488 ± 0.002 0.518 ± 0.02
5-HT7 0.455 ± 0.04 0.450 ± 0.03 0.302 ± 0.02 0.899 ± 0.04 0.902 ± 0.03 0.523 ± 0.02
5-HT6 0.461 ± 0.03 0.455 ± 0.02 0.309 ± 0.00 0.520 ± 0.00 0.507 ± 0.00 0.544 ± 0.01
MT1A 0.630 ± 0.12 0.622 ± 0.13 0.365 ± 0.02 0.769 ± 0.10 0.761 ± 0.10 0.596 ± 0.03
MT1B 0.630 ± 0.06 0.623 ± 0.05 0.351 ± 0.02 0.856 ± 0.13 0.839 ± 0.12 0.586 ± 0.02
CB1 0.494 ± 0.05 0.486 ± 0.05 0.343 ± 0.01 0.584 ± 0.03 0.578 ± 0.03 0.565 ± 0.03
MOR 0.538 ± 0.06 0.528 ± 0.06 0.380 ± 0.01 0.663 ± 0.06 0.643 ± 0.06 0.645 ± 0.02
DOR 0.473 ± 0.01 0.466 ± 0.01 0.380 ± 0.00 0.614 ± 0.03 0.605 ± 0.03 0.636 ± 0.01
KOR 0.513 ± 0.04 0.500 ± 0.04 0.375 ± 0.01 0.651 ± 0.04 0.636 ± 0.04 0.629 ± 0.03
CB2 0.542 ± 0.03 0.525 ± 0.03 0.343 ± 0.01 0.641 ± 0.03 0.627 ± 0.03 0.601 ± 0.02
MC4 0.407 ± 0.04 0.396 ± 0.04 0.361 ± 0.00 0.540 ± 0.03 0.526 ± 0.04 0.589 ± 0.01
mGluR5 0.628 ± 0.11 0.627 ± 0.11 0.332 ± 0.02 0.720 ± 0.09 0.713 ± 0.09 0.524 ± 0.03
CCR2 0.417 ± 0.08 0.409 ± 0.08 0.285 ± 0.02 0.546 ± 0.20 0.539 ± 0.20 0.534 ± 0.03
B1 0.578 ± 0.15 0.576 ± 0.16 0.320 ± 0.03 0.722 ± 0.18 0.722 ± 0.17 0.618 ± 0.04
MC5 0.484 ± 0.11 0.471 ± 0.10 0.433 ± 0.03 0.428 ± 0.11 0.423 ± 0.10 0.578 ± 0.04
MC3 0.339 ± 0.06 0.343 ± 0.06 0.413 ± 0.02 0.422 ± 0.09 0.418 ± 0.08 0.542 ± 0.02
OX2R 0.445 ± 0.04 0.439 ± 0.04 0.307 ± 0.01 0.562 ± 0.06 0.550 ± 0.06 0.599 ± 0.01
OX1R 0.340 ± 0.04 0.336 ± 0.03 0.325 ± 0.01 0.510 ± 0.05 0.500 ± 0.05 0.570 ± 0.01
Table 2. Regression results obtained for BAC.
Target Morgan FP MACCSFP
MSE Dropout MSE Uncertainty MSE Dropout MSE Uncertainty
5-HT1A 1.323 ± 0.21 1.284 ± 0.18 0.347 ± 0.04 1.879 ± 0.10 1.746 ± 0.03 0.563 ± 0.07
ACM1 1.788 ± 0.43 1.766 ± 0.41 0.389 ± 0.07 2.792 ± 0.80 2.706 ± 0.73 0.594 ± 0.09
D2 0.967 ± 0.16 0.954 ± 0.16 0.342 ± 0.02 1.424 ± 0.26 1.304 ± 0.15 0.588 ± 0.04
5-HT2A 1.667 ± 0.56 1.609 ± 0.57 0.395 ± 0.04 1.496 ± 0.00 1.449 ± 0.00 0.568 ± 0.00
5-HT2C 1.534 ± 0.75 1.502 ± 0.72 0.338 ± 0.04 1.714 ± 0.44 1.671 ± 0.44 0.517 ± 0.01
A1 1.378 ± 0.56 1.359 ± 0.56 0.337 ± 0.03 1.602 ± 0.00 1.537 ± 0.00 0.476 ± 0.00
A2A 1.445 ± 0.37 1.430 ± 0.36 0.367 ± 0.03 1.264 ± 0.19 1.207 ± 0.19 0.567 ± 0.02
H3 1.001 ± 0.13 0.961 ± 0.13 0.354 ± 0.02 1.284 ± 0.46 1.205 ± 0.43 0.547 ± 0.05
5-HT7 1.267 ± 0.53 1.252 ± 0.54 0.316 ± 0.03 2.027 ± 0.65 1.956 ± 0.63 0.534 ± 0.04
5-HT6 1.337 ± 0.39 1.305 ± 0.38 0.323 ± 0.03 1.597 ± 0.41 1.453 ± 0.44 0.564 ± 0.03
MT1A 1.989 ± 0.54 1.989 ± 0.55 0.367 ± 0.06 2.101 ± 0.60 2.071 ± 0.59 0.532 ± 0.04
MT1B 1.921 ± 0.27 1.914 ± 0.28 0.340 ± 0.06 1.925 ± 0.42 1.899 ± 0.43 0.565 ± 0.06
CB1 1.413 ± 0.44 1.399 ± 0.41 0.351 ± 0.03 1.595 ± 0.49 1.511 ± 0.43 0.563 ± 0.02
MOR 1.602 ± 0.30 1.546 ± 0.30 0.405 ± 0.02 1.994 ± 0.38 1.878 ± 0.38 0.653 ± 0.05
DOR 1.921 ± 1.01 1.895 ± 0.99 0.360 ± 0.02 2.393 ± 1.07 2.251 ± 0.94 0.607 ± 0.05
KOR 1.653 ± 0.43 1.613 ± 0.42 0.401 ± 0.03 2.159 ± 0.86 2.052 ± 0.79 0.651 ± 0.05
CB2 1.601 ± 0.41 1.577 ± 0.43 0.350 ± 0.02 1.552 ± 0.41 1.508 ± 0.38 0.619 ± 0.08
MC4 1.652 ± 0.87 1.561 ± 0.78 0.392 ± 0.07 1.406 ± 0.49 1.371 ± 0.48 0.577 ± 0.07
mGluR5 2.289 ± 1.08 2.279 ± 1.08 0.336 ± 0.05 1.844 ± 0.71 1.839 ± 0.73 0.488 ± 0.07
CCR2 0.792 ± 0.43 0.789 ± 0.43 0.288 ± 0.05 1.480 ± 0.60 1.428 ± 0.57 0.411 ± 0.04
B1 1.903 ± 0.65 1.894 ± 0.66 0.353 ± 0.05 1.503 ± 0.42 1.478 ± 0.42 0.597 ± 0.16
MC5 1.221 ± 1.12 1.237 ± 1.13 0.441 ± 0.04 1.230 ± 1.35 1.207 ± 1.31 0.504 ± 0.02
MC3 0.947 ± 0.41 0.913 ± 0.39 0.482 ± 0.05 0.917 ± 0.43 0.895 ± 0.42 0.533 ± 0.05
OX2R 1.192 ± 0.64 1.183 ± 0.63 0.291 ± 0.02 1.573 ± 0.84 1.582 ± 0.87 0.547 ± 0.05
OX1R 1.178 ± 0.57 1.164 ± 0.56 0.345 ± 0.05 1.833 ± 0.14 1.778 ± 0.13 0.569 ± 0.08
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The results gathered in Tables 1 and 2 show that in general, MSE values were much higher for BAC
splitting than random CV, which is related to increased task simplicity when compounds are divided into
folds randomly [35]. In BAC splitting, the compounds from the test set are supposed to be structurally
dissimilar to those that are present in the training set; therefore, via this approach we can evaluate the
true ability of ML models to assess compounds covering broad chemical space. Nevertheless, using
such an approach for ML methods evaluation is always related to worse performance, as CV-based
output provides overoptimistic results (the compounds from the test set resemble examples from the
training set, so the evaluation task is relatively simple) that are not reflected in real application of
such models.
Interestingly, MSE values obtained for MACCSFP are higher in both CV and BAC splitting in
comparison to hashed Morgan FP representation. The difference is higher for BAC splitting, but it is
related to higher MSE values for these experiments.
Another consistent observation is that MSE is higher than dropout MSE, which means that the
non-deterministic MSE is lower than its deterministic equivalent. It can be explained in such a way,
that multiple drawing of dropout’s masks is identical to the prediction of the network committee,
which usually is characterized by slightly better results.
Our last observation is connected with uncertainty evaluation. It also reaches higher values for BAC
experiments in comparison to CV, while on the other hand, when different compound representations
are compared, uncertainty values are higher for MACCSFP in comparison to Morgan FP.
When the results are examined from the target point of view, the highest error rate is observed for
ACM1, mGluR5, ACM1 and ACM2 for both representations and splitting approaches and the lowest
for D2 and MC3. In general, smaller datasets led to worse prediction efficiency.
2.2. Analysis of Uncertainties, Errors and Compound Similarities
The visualization of dependencies between the regression error, similarity to the training set
(calculated for Morgan FP and with the use of Tanimoto coefficient) and uncertainty was performed
(Figure 1, Supporting Information File S1).
The first observation coming from Figure 1 is that there is no significant difference between results
obtained for two representation used—the only qualitative and strong indicated differentiation is the
uncertainty vs. similarity dependence for random CV, which is spread over greater area for Morgan
FP than MACCSFP. For this dependency it is also visible that the data points are placed differently
when random CV vs. BAC splitting is considered—for random CV, the datapoints are concentrated
closer to higher values of similarity coefficients, whereas for BAC they are spreading from the corner
with lower similarity and uncertainty values. The highest concentration of datapoints in lower values
of both parameters considered (MSE and uncertainty) is also observed for MACCSFP and random
CV; for other combinations of dataset splitting approach and representation the datapoints cover
much broader space of the respective chart although and MSE is more concentrated parameter than
uncertainty, which adopts quite broad range of values. MSE vs. similarity charts also much more
depended on the splitting approach than the compound representation and the highest concentration
of points is shifted towards higher similarity values for random CV than for BAC.
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MACCSFP in BAC.
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Another type of analysis involved the examination of relationships between the number of
different activity values reported and average prediction uncertainty (Figure 2, Supporting Information
File S2). In the case, no ‘box’ is presented on the chart, only one compound was reported for particular
number of activity values. Activity range is shown by lines, box size refers to first and last quartile and
orange line to median activity value. The results show that there is no direct relationship between the
number of activity values provided for particular compound and uncertainty of predictions obtained
for them, for both random CV and BAC. No direct conclusion that increasing number of activity values
reported led to higher uncertainty can be drawn.
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Last type of analysis involved the examination of correlation between the standard deviation
of activity values reported for given compound and prediction uncertainty (Figure 3, Supporting
Information File S3).
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The first observation coming from Figure 4 is that the consistency in data in training set (standard
deviation of activity lues equal to zero) is not related to clear a d c rtain predictions for given
compoun and wide range of uncertainty is ssign d to compounds with standard deviation of activity
valu s equal to zero. Furth r, there is no correlation betwe n standard deviation and uncertainty of
predi tions and even for compounds with wide ange of activity values reported, predictions with low
uncertainty can be obtained.
2.3. Compounds Ranking
In this experiment, we sorted compounds using particular strategy and the results were compared
with the sorting based on true activities. The baseline model performs sorting only on the basis of
prediction of a model, remaining strategies use also information about model uncertainty in various
ways. It was indicated that using information about uncertainty in general improves sorting efficiency.
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For the ranking strategies, we will assume that yˆi is the predicted bioactivity (in terms of affinity
values—Ki) and ui is the prediction uncertainty. We will denote R(yˆi,ui) as output of ranking function,
meaning the lower the R value, the higher in our ranking the compound is.
The following ranking strategies were used:
• Baseline—only prediction of a model is taken into account
R(yˆi,ui)= yˆi (1)
• Add—to model prediction, information about uncertainty is added directly; the less uncertain the
model is about the sample, the better
R(yˆi,ui) = yˆi + ui (2)
• Scale—the uncertainty estimation is normalized to fit the range of [0,1]) and used to scale the
prediction
R(yˆi,ui) = u˜i ∗ yˆi (3)
u˜i =
ui −min
j
u j
max
j
u j
, (4)
where u˜i is a normalized uncertainty based on the measures for the whole test set.
• Add scaled—the uncertainty estimation is normalized to fit into [0,1] and added directly to the
prediction
R(yˆi,ui) = u˜i + yˆi (5)
• Sum scaled—both prediction of a model and its uncertainty are normalized and then summed up
R(yˆi,ui) = u˜i + y˜i
y˜i =
yi−min
j
y j
max
j
y j
where y˜i is a normalized prediction based on the predictions over the whole dataset.
• Comb λ—linear combination of prediction and uncertainty with the λ coefficient (various λ values
were tested).
R(yˆi,ui) = λyˆi + (1− λ)ui (6)
The results are presented in the form of the so-called “precision at top 10%”, which means that
the compounds are sorted on the basis of their activity (two lists are prepared: based on true activity
and based on the predicted values of activity parameters). Then, the 10% of top scored compounds
from the list of the most active compounds is picked up and it is cross-checked with the list of the
10% of top scored compounds on the basis of predicted activity. The percentage of overlapping
compounds between these two lists for different strategies for BAC splitting for example targets is
gathered in Figure 4.
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We can notice that the results and prediction effectiveness strongly depend both on the target,
as well as compound representation. For all targets presented in Figure 4 Morgan FP appeared to be
more effective representation. The differences in precision between different compound representations
also vary for various targets—from slight differences for 5-HT2C, via a ~0.1 difference for M1, A1, H3
and 5-HT7, to up to 0.15 difference for 5-HT1A. On the other hand, the differences related to various
compound representations were higher than differences related to application of different approaches.
When information on uncertainty is added, the precision values averaged over all targets considered
revealed that for both compound representations _add approach was the best. Nevertheless, in both
cases, the improvement in comparison to baseline was relatively low—0.004 and 0.007 for MorganFP
and MACCSFP, respectively when averaged values for all targets are taken into account.
However, considering particular cases separately, there was an approach that improved the
accuracy of ML predictions in comparison to baseline; there were examples where these improvement
was quite significant. For example, for D2 and H3 ligands, precision at top 10% was higher by ~0.03
when _sum_scaled approach is compared to baseline (for Morgan FP). _sum_scaled approach gave the
highest improvement over baseline for A2A, for MACCSFP representation (~0.04).
In order to examine the influence of incorporation of uncertainty into ML models, the heat maps
were prepared comparing the precision at top 10% for baseline and other approaches (Figure 5).
Figure 5 clearly show that in the majority of cases incorporation of information about prediction
uncertainty improved efficiency of predictions of ML models (indicated by pink and red cells on heat
maps). Nevertheless, the results strongly depend on target and compound representation. For M1,
A2A and 5-HT6, strong improvement is observed for MACCSFP; for Morgan FP, it was D2, A2A and H3
that led to the highest improvement. This effect (for both representations is observed mainly for _add,
_add_scaled and _sum_scaled approaches. On the other hand, the _sum_scaled approach was the
only one for which the worsening of the results was observed for some targets (M1, A1 and 5-HT6 for
Morgan FP and M1 and 5-HT2C for MACCSFP).
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2.4. Detection of Potential Errors in Bioactivity Databases
The developed methodology was used for detection of potential errors in the ChEMBL database.
First of all, for all targets considered, the MSE of activity prediction together with uncertainties were
calculated for the test set (Figure 6).
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Figure 6. Analysis of uncertainty and MSE of activity prediction (calculated for all targets considered).
(a) uncertainty; (b) prediction error expressed as log(MSE).
On the basis of these data, the ‘suspected’ data points were indicated; they were defined as
those for which the MSE was in the 95 percentile (and higher) and uncertainty on the 5th percentile
(and higher).
Examples of such compounds—together with the true activities reported and activities of 10 most
similar compounds—are presented below (Figure 7).
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Figure 7. Analysis of selected dopamine D2 ligands with terms of affinity values provided in ChEMBL,
predicted activity, prediction uncertainty and activity of structurally similar ligands (for Morgan FP).
The provided examples of dopamine D2 ligands prove that the prediction uncertainty is not
correlated with the standard deviation of activity values provided in activity databases. For ligand
CHEMBL156651, there were 8 Ki values towards D2 receptor reported, ranging from 0.067 nM to
260 nM (with the average Ki equal to 106.23 nM) and standard deviation of 108 nM. The predicted Ki for
this compound is however much lower than the actual affinity values and is equal to 11.11 nM which
is expressed also by high uncertainty factor (0.708). The relatively low value of predicted Ki is a result
of activities of similar compounds present in the dataset. Figure 7 presents only selected examples,
but even among them can be found compounds with much lower Ki than actual average Ki, such as
CHEMBL139089, for which two Ki values are reported (37 and 68.2 nM). On the other hand, there
is compound CHEMBL317433, for which only one Ki value is available (0.2 nM). Although for this
compound, the standard deviation of Ki values is equal to zero, the prediction uncertainty is similar
to the uncertainty determined for CHEMBL156651 (0.211) and the predicted Ki for this compound is
equal to 80.85 nM. In this case, the activity of similar compounds is in narrower range, as the most
active CHEMBL194844 has affinity of 5.1 nM, but there is also CHEMBL196171, whose Ki is equal to
21 nM.
3. Materials and Methods
The ChEMBL database [9] was used as a data source. Experiments were performed on 10 target
proteins that were previously subject to detailed study in terms of dataset preparation for ML
experiments [35]: serotonin receptors 5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, 5-HT7 [50–53], muscarinic
receptor ACM1 [54], adenosine receptors A1 [55] and A2A [56,57], histamine receptor H3 [58] and
dopamine receptor D2 [59,60]. The targets are mostly representatives of aminergic GPCRs and
were selected due to the knowledge of ligands of these receptors and the datasets themselves due
to previous studies performed on these targets [35]. In addition, 15 proteins covering also other
GPCRs’ families were selected to minimize results bias related to target selection: bradykinin B1
receptor [61], melanocortin (MC) receptors subtype 3, 4 and 5 [62], kappa opioid receptor (KOR) [63,64],
mu opioid receptor (MOR) [64], delta opioid receptor (DOR) [64] orexin receptors 1 and 2 (OX1R,
OX2R) [65], cannabinoid CB1 receptor [66], cannabinoid CB2 receptor [66], melatonin receptors MT1A
and MT1B [67], metabotropic glutamate receptor mGluR5 [68] and C-C chemokine receptor type 1
(CCR1) [69,70]. The respective datasets were extracted using the following protocol: all records referring
to human-related data were gathered and all cases that were not describing binding data (activity
parameter included in the list: Ki, log(Ki), pKi, IC50, log(IC50), pIC50) were filtered out. Then, only
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‘equal to’ relation between activity parameter and its value were kept and units of activity parameters
values should belong to the set {M, mM, µM, nM, pM, fM}; additional results were produced for
extended set of relations between activity parameter and its value (“=”, “<”, “>”, “≤”, “≥”, “~”)—the
results are presented in the Supporting Information and were obtained for the set of 10 targets
from benchmark studies. Recalculation of IC50 into Ki was performed using the following formula:
Ki = IC50/2 [35] Finally, the Ki values were converted to the logarithmic form and such datasets were
used in the study.
The predictions were carried out in two settings: random CV and BAC [35]. The compounds
structures were represented by Morgan Fingerprint (radius equal to 2) [71] and MACCSFP [72]
calculated by RDKit [73]. The dataset sizes in these two splitting types are presented in Table 3.
Table 3. Size of datasets used in the study.
Target
CHEMBLID Target Name
Training Set
Size CV
Test Set Size
CV
Training Set
Size BAC
Test Set Size
BAC
CHEMBL214 5-HT1A 2599 649 2495 753
CHEMBL216 ACM1 676 168 652 192
CHEMBL217 D2 4496 1124 4243 1379
CHEMBL224 5-HT2A 2385 596 2025 956
CHEMBL225 5-HT2C 1559 389 1590 358
CHEMBL226 Adenosine A1 2782 695 2758 719
CHEMBL251 Adenosine A2A 3165 791 2915 1041
CHEMBL264 Histamine H3 2546 636 2689 493
CHEMBL3155 5-HT7 1209 302 1070 441
CHEMBL3371 5-HT6 2074 518 1979 613
CHEMBL1945 MT 1A 573 143 622 94
CHEMBL1946 MT 1B 572 142 524 190
CHEMBL218 CB1 1945 486 1950 481
CHEMBL233 MOR 2815 703 2997 521
CHEMBL236 DOR 2457 614 2070 1001
CHEMBL237 KOR 2381 595 2147 829
CHEMBL253 CB2 2611 652 2687 576
CHEMBL259 MC4 1450 362 1364 448
CHEMBL3227 mGluR5 272 67 283 56
CHEMBL4015 CCR2 168 42 180 30
CHEMBL4308 B1 444 110 431 123
CHEMBL4608 MC5 314 78 334 58
CHEMBL4644 MC3 400 99 410 89
CHEMBL4792 OX2R 1269 317 1175 411
CHEMBL5113 OX1R 1087 271 1182 176
The problem considered in the study is numerical regression of bioactivity of ligands toward a
particular target. For all of the experiments we used the same model architecture, a 3-hidden layer
Multi-layer Perceptron with following hidden layer sizes: 500, 500, 200 and a single-neuron regression
output layer. After each fully connected layer, except the final output layer, there was an ReLU
nonlinearity activation function. Additionally, to enable uncertainty estimation, after each hidden layer,
there is a dropout layer with probability of a neuron to be dropped set to 0.5 (Scheme 1), according to
Gal et al. [46]. No additional regularization penalty were used throughout the training procedure. For
the learning process, data points were supplied in mini batches of 100 examples, Adam method [74]
was used for the optimizer with learning rate set to 0.001, each model was trained for 200 epochs.
For each protein-representation pair a 5-fold cross-validation scheme was performed using two different
splitting strategies mentioned in the earlier (random CV, BAC). The model, the training procedure as
well as the uncertainty estimation algorithm was implemented using DeepChem package [75]. If a
specific hyperparameter value is not mentioned, the default value provided by DeepChem was used.
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uncertainty for compounds indicated as potentially active might have crucial impact on making decision
about their purchase.
Supplementary Materials: The following are available online. File S1. Visual analysis of dependencies between
MSE, prediction uncertainty and compound similarity for all targets considered in the study for only ‘=’ relation
between activity parameter and its value; File S2. Analysis of dependency between prediction uncertainty and
number of activity values provided for particular compound in the ChEMBL database for all targets considered
in the study for only ‘=’ relation between activity parameter and its value; File S3. Analysis of dependency
between prediction uncertainty and standard deviation of activity values provided for particular compound in the
ChEMBL database for all targets considered in the study for only ‘=’ relation between activity parameter and its
value. File S4. Visual analysis of dependencies between MSE, prediction uncertainty and compound similarity for
benchmark targets for extended set of relations between activity parameter and its value. File S5. Analysis of
dependency between prediction uncertainty and number of activity values provided for particular compound in
the ChEMBL database for benchmark targets for extended set of relations between activity parameter and its
value; File S6. Analysis of dependency between prediction uncertainty and standard deviation of activity values
provided for particular compound in the ChEMBL database for benchmark targets for extended set of relations
between activity parameter and its value.
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